Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stephanie Lindeman

Physician Assistant, Surgical Arlington Heights, IL Physician Assistant

NPI 1538404454 CMS profile 11221480

880 W Central Rd, Suite 3800, Arlington Heights, IL 60005

Open in the dashboard

General payments

$7,423

396 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephanie Lindeman of Arlington Heights, IL is reported in the CMS Open Payments database as having received $7,423 across 396 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,149 97
2024 General $1,334 72
2023 General $1,259 68
2022 General $1,356 76
2021 General $1,324 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephanie Lindeman
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Stephanie Lindeman were reported at $2,149. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Stephanie Lindeman Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,324 $111 $36–$285 $132
2022 $1,356 $126 $44–$350 $149
2023 $1,259 $137 $47–$355 $160
2024 $1,334 $146 $49–$384 $164
2025 $2,149 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,221 65 payments
  2. AbbVie, Inc. $1,203 73 payments
  3. Lilly USA, LLC $939 60 payments
  4. Genzyme Corporation $614 26 payments
  5. Pfizer Inc. $534 29 payments
  6. Novartis Pharmaceuticals Corporation $495 29 payments
  7. Regeneron Healthcare Solutions, Inc. $316 15 payments
  8. Mayne Pharma Inc. $285 14 payments
  9. Sun Pharmaceutical Industries Inc. $269 9 payments
  10. LEO Pharma Inc. $247 14 payments
  11. Other $1,301 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,667 387 payments
  2. Education $756 9 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,140 61 payments
  2. TALTZ $924 59 payments
  3. DUPIXENT Immunology $901 34 payments
  4. SKYRIZI $459 24 payments
  5. CIBINQO $429 23 payments
  6. HUMIRA $420 30 payments
  7. EBGLYSS $391 18 payments
  8. RINVOQ $343 22 payments
  9. EUCRISA $298 18 payments
  10. DUPIXENT Inflammation And Immunology $253 13 payments
  11. Other $3,250 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

112

Median for Physician Assistant: 241

Drug cost

$1,841

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 51 $1,031
Clindamycin Phosphate Generic 13 $435
Ketoconazole Generic 21 $259
Mupirocin Generic 11 $59
Triamcinolone Acetonide Generic 16 $57

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $351
$351 — —
DUPIXENT
  • GENZYME CORPORATION $132
  • Regeneron Healthcare Solutions, Inc. $25
$157 — —
TALTZ
  • Lilly USA, LLC $90
$90 — —
SKYRIZI
  • AbbVie, Inc. $83
$83 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

396 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record